SEC Comment Letter 0000000000-23-012077 to AlphaTON Capital Corp (ATON)
AlphaTON Capital Corp
Date: Nov. 3, 2023 · CIK: 0001095435 · Accession: 0000000000-23-012077
AI Filing Summary & Sentiment
File numbers found in text: 333-275229
Letter
United States securities and exchange commission logo November 3, 2023 Ian Walters, MD, MBA Chief Executive Officer Portage Biotech Inc. Clarence Thomas Building, P.O. Box 4649 Road Town, Tortola British Virgin Islands, VG1110 Re:Portage Biotech Inc. Registration Statement on Form F-1 Filed October 31, 2023 File No. 333-275229 Dear Ian Walters: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steve Abrams
Show Raw Text
United States securities and exchange commission logo
November 3, 2023
Ian Walters, MD, MBA
Chief Executive Officer
Portage Biotech Inc.
Clarence Thomas Building, P.O. Box 4649
Road Town, Tortola
British Virgin Islands, VG1110
Re:Portage Biotech Inc.
Registration Statement on Form F-1
Filed October 31, 2023
File No. 333-275229
Dear Ian Walters:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steve Abrams